Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
2026-10-10 22:15
•Adria Cimino •The Motley Fool
••• •• Axe Cap view
Moderna Surpasses Price Targets—Is It Time to Sell?
Moderna’s stock has skyrocketed but may face turbulence despite strong long-term prospects.
Moderna’s 500% rally this year has pushed its price well beyond Wall Street’s average expectations—over 60% higher. While the biotech’s pioneering work on personalized cancer vaccines and its mRNA platform has real long-term potential, such a steep premium suggests some caution. South African investors often look for earnings stability and predictable growth, but Moderna’s path is still tied to clinical trial outcomes and manufacturing scale-up. This makes near-term volatility likely. For those watching the rand, a tech rebound in the US often strains USD/ZAR, which could increase costs for local funds holding offshore assets. Buying now means accepting a speculative ride more than a safe bet. If you’re holding, stay nimble and trim if your position size feels too stretched. That said, if trials continue succeeding and Moderna captures market share beyond Covid vaccines, there’s upside ahead. But overpaying at this stage can hurt. this is just our opinion and not financial advice
Trim exposure to Moderna for now to lock in gains. Watch USD/ZAR trends closely because a stronger rand could ease import costs of offshore biotech holdings.
- MRNA
- USD/ZAR
- Clinical trials may fail or delay approval, hitting share price hard
- USD strength increasing rand weakness, raising offshore holding costs
6/10
Moderna stock has surged over 500% this year, driven by investor enthusiasm about its personalized cancer vaccine candidate. The stock now trades 61% above Wall Street's average price target. While the stock may face near-term pullback after its rapid gains, the company's strong pipeline and long-term growth potential in mRNA-based therapies suggest it remains a solid long-term biotech investment, though scaling personalized vaccines presents manufacturing challenges.
Our take is based on reporting first published by The Motley Fool.